NMC Health’s (NMC) “Overweight” Rating Reaffirmed at Barclays
Several other brokerages also recently issued reports on NMC. Berenberg Bank reiterated a buy rating and issued a GBX 3,600 ($47.04) price objective on shares of NMC Health in a research report on Thursday, August 22nd. Societe Generale reissued a buy rating on shares of NMC Health in a research note on Tuesday, August 27th. Finally, Jefferies Financial Group lowered their target price on NMC Health from GBX 2,077 ($27.14) to GBX 1,986 ($25.95) and set an underperform rating for the company in a research note on Tuesday, July 9th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. NMC Health presently has a consensus rating of Buy and an average target price of GBX 3,740.20 ($48.87).
Shares of NMC opened at GBX 2,828 ($36.95) on Monday. The stock has a fifty day moving average price of GBX 2,274.49 and a two-hundred day moving average price of GBX 2,449.53. The company has a debt-to-equity ratio of 165.90, a quick ratio of 1.43 and a current ratio of 1.70. NMC Health has a 52-week low of GBX 1,773.50 ($23.17) and a 52-week high of GBX 3,764 ($49.18). The company has a market cap of $5.90 billion and a price-to-earnings ratio of 21.92.
NMC Health Plc provides healthcare services in the United Arab Emirates, Spain, and internationally. The company operates through two businesses, NMC Healthcare and NMC Trading. It owns and manages approximately 135 healthcare facilities that include hospitals, medical centers, long term care facilities, day surgery centers, fertility centers, and home health services providers.
Featured Article: Does the Dogs of the Dow strategy work?
Receive News & Ratings for NMC Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NMC Health and related companies with MarketBeat.com's FREE daily email newsletter.